Jazz Pharmaceuticals completes Actio deal: what it means for Jazz Pharmaceuticals stock
Jazz Pharmaceuticals has completed its acquisition of Actio Biosciences for an upfront payment of $820 million, adding an experimental therapy for KCNT1-related epilepsy to its pipeline. The company also reported record second-quarter 2026 revenue of $1.21 billion and raised its full-year revenue guidance. Despite a recent analyst downgrade, Jazz Pharmaceuticals stock maintains a consensus price target significantly above its current trading price.
Jazz Pharmaceuticals stock expands epilepsy pipeline after Actio deal
Jazz Pharmaceuticals acquired Actio Biosciences for $820 million, adding ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to its pipeline. This acquisition follows a strong Q2 2026 where Jazz reported $1.21 billion in revenue, although EPS missed consensus estimates. Analysts maintain a "Buy" rating with an average 12-month price target of $294.27, despite the stock trading below its yearly high.
Jazz Pharmaceuticals plc (J7Z.F) Stock Price, News, Quote & History
This article provides a detailed financial overview of Jazz Pharmaceuticals plc (J7Z.F), including its stock price, historical data, and performance metrics. It highlights the company's product portfolio for various conditions like narcolepsy, epilepsy, and cancer, along with its pipeline of developmental drugs. The report also includes key financial figures, earnings trends, and a comparison of its returns against the S&P 500.
Jazz Pharmaceuticals (JAZZ), The Latest Update Raises A Bigger Question
Jazz Pharmaceuticals reported strong quarterly revenue of US$1.21 billion, exceeding forecasts and leading to higher full-year guidance. Despite this positive financial update, the stock price has fallen, prompting investors to re-evaluate how much of the company's earnings strength was already factored into its valuation after a significant year-to-date return. The company is considered 19% undervalued with an implied fair value of $289.45, driven by anticipated new therapy approvals and expansion in its neuroscience/sleep portfolio, though risks such as patent expiries and potential underdelivery of new launches remain.
After a $1.5M September sale, Jazz Pharmaceuticals (NASDAQ: JAZZ) officer proposes another.
Bruce C. Cozadd, an officer at Jazz Pharmaceuticals (NASDAQ: JAZZ), has reported a proposed sale of 6,000 common shares valued at approximately $1.38 million, scheduled for October 1, 2026. This follows earlier sales of 6,000 shares each in July, August, and September 2026, which generated gross proceeds of $1.44 million, $1.51 million, and $1.50 million respectively. The filing details show the company has 64,914,577 common shares outstanding, with stock options for Cozadd dating back to 2018 and 2025.
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
The article analyzes the Q2 earnings performance of pharmaceuticals stocks, highlighting Jazz Pharmaceuticals (NASDAQ:JAZZ) as a strong performer with revenues up 15.5% year-on-year, though its stock price dipped post-earnings. Bristol-Myers Squibb (NYSE:BMY) also had an impressive quarter, while Zoetis (NYSE:ZTS) was the weakest performer with flat revenues and missed expectations. The pharmaceuticals sector as a whole reported strong Q2 results, with revenues beating estimates by 5.5%.
Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE)
Citi has initiated coverage on Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings, citing the strong prospects of their oncology products, Ibtrozi and Ziihera, respectively. This move is part of a broader review of the U.S. biopharma sector by Citi analyst Geoff Meacham, highlighting potential growth in these companies.
Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target
Citigroup has initiated coverage of Jazz Pharmaceuticals with a "Buy" rating and set a price target of $325. This news comes amidst a period of significant activity for Jazz Pharmaceuticals, including recent presentations at healthcare summits and the completion of a major acquisition. The company, a global biopharmaceutical firm, focuses on developing treatments for serious diseases, particularly in sleep disorders, epilepsy, and cancer.
Jazz Pharmaceuticals stock reports record Q2 revenue growth
Jazz Pharmaceuticals (JAZZ) reported a record 16% increase in Q2 2026 revenue, reaching $1.2083 billion, driven by growth across its sleep, epilepsy, and oncology products. The company also raised its full-year 2026 revenue guidance to $4.60 billion - $4.75 billion and expanded its pipeline with the acquisition of Actio Biosciences for $820 million. Despite strong operating growth, acquisition-related costs impacted adjusted EPS for the quarter.
Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.com
Goldman Sachs has initiated coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a buy rating and a $337 price target, citing strong performance and future growth prospects from new drug launches. The company, known for its neuroscience and oncology assets, has seen its stock return 81% over the past year and boasts impressive gross profit margins of 91%. Recent approvals for Ziihera in gastroesophageal adenocarcinoma and other pipeline developments like Modeyso are expected to drive significant market opportunities.
Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and Recommendations
This article provides a summary of recent analyst ratings and recommendations for Jazz Pharmaceuticals PLC (J7Z.HA), including price targets and an overview of whether analysts maintain or upgrade their ratings. It shows several firms like UBS, Barclays, Deutsche Bank, Morgan Stanley, Truist Securities, and Needham maintaining "Buy" or "Overweight" ratings for the company in September and August 2026. The stock was trading at 204.50 EUR, down 1.35% at market close on September 24.
Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033
Jazz Pharmaceuticals has extended and repriced its U.S. dollar term loan, converting Tranche B-2 into a new $1.895 billion Tranche B-3. This change moves the maturity date to May 5, 2033, and reduces the interest margins by 50 basis points. The company also borrowed an additional $273.3 million to repay non-converted loans, aiming to enhance financial flexibility and lower interest expenses.
Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins.
Jazz Pharmaceuticals has amended its credit agreement, extending the maturity of approximately $1.9 billion in U.S. dollar term loans from 2028 to May 5, 2033. The revised terms also include a reduction of 50 basis points in the applicable borrowing margins. This move provides the company with more time to repay its debt and reduces its borrowing costs.
Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus
Jazz Pharmaceuticals (JAZZ) is drawing investor attention with its share price at $240.57, despite mixed short-term moves, due to strong longer-term returns. The company is considered 17% undervalued with a fair value of $289.45, supported by its product pipeline. However, concerns exist regarding patent expiries, generic competition, and debt, while its P/E ratio is slightly above the US average but well below peers.
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: A Biotech Powerhouse with 20% Upside Potential
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is highlighted as a compelling investment opportunity in the biotech sector, offering a potential 20.71% upside. The company's strong financial health is supported by a robust product pipeline, significant free cash flow, and positive analyst sentiment with an average target price of $290.60. Its strategic collaborations and innovative treatments across neurology and oncology position it for continued growth and capital appreciation.
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
Jazz Pharmaceuticals recently acquired Actio Biosciences for $820 million, adding ABS-1230, a clinical-stage epilepsy drug, to its pipeline. This acquisition follows a record-breaking quarter for Jazz, with revenue reaching $1.2 billion and increased full-year guidance. While the deal expands Jazz's rare disease and oncology portfolio, it also adds to its long-term debt and the drug itself is still in early clinical stages.
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences
Jazz Pharmaceuticals has completed its acquisition of Actio Biosciences for an upfront payment of $820 million, gaining Actio's lead asset, ABS-1230. This acquisition adds a rare, genetically defined epilepsy program to Jazz's portfolio, with ABS-1230 being a clinical-stage oral small molecule showing promise for KCNT1-related epilepsy. Actio's other programs were spun out into a new independent company, with Jazz retaining a minority stake.
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com
This article announces that Jazz Pharmaceuticals plc filed a Form 8K on September 15. The content of the 8K filing itself is not detailed, but the article provides the date and company name for the filing.
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com
This article reports that Jazz Pharmaceuticals plc filed a Form 8K on September 15th. The filing is a standard regulatory announcement that companies make to disclose material events or information to investors. The article itself is a very brief notification of this event, indicating it was published by Investing.com.
Form 8K Jazz Pharmaceuticals plc For: 15 September By Investing.com
This article reports that Jazz Pharmaceuticals plc filed a Form 8K on September 15. The brief piece includes the stock symbol JAZZ and its current performance. The content is primarily a placeholder, suggesting more detailed information would typically be found in the actual SEC filing.
Jazz Pharmaceuticals completes Actio Biosciences acquisition
Jazz Pharmaceuticals (NASDAQ:JAZZ) has finalized its acquisition of Actio Biosciences for $820 million, integrating Actio's clinical-stage KCNT1 inhibitor, ABS-1230, into its epilepsy pipeline. ABS-1230 is designed to treat KCNT1-related epilepsy, a rare condition, and has received several FDA designations including Fast Track. As part of the deal, Actio's non-ABS-1230 programs were spun off into a new entity, in which Jazz holds a minority stake.
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals has completed its acquisition of Actio Biosciences for $820 million upfront, integrating Actio as a wholly-owned subsidiary. This acquisition brings ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, into Jazz's pipeline, strengthening its rare disease portfolio. ABS-1230 has shown promising results in preclinical studies and early clinical trials, with potential to significantly reduce seizures in affected children and has received several FDA designations.
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock
An officer at Jazz Pharmaceuticals (JAZZ), Neena Patil, plans to sell 1,200 shares of common stock under Rule 144, valued at $289,128. These shares were acquired as restricted stock on March 5, 2026, and are slated for sale on NASDAQ by September 10, 2026. The transaction will be processed through Morgan Stanley Smith Barney LLC Executive Financial Services.
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery
S&P Global Ratings upgraded Jazz Pharmaceuticals PLC's senior secured debt to 'BB+' from 'BB' and assigned a 'BB+' rating to a proposed $1.9 billion term loan, citing a stronger recovery outlook. The upgrade reflects a higher valuation and increased cushion for secured debt holders, with the company maintaining a 'BB' issuer credit rating and stable outlook. This is supported by Jazz's expected revenue growth, strong adjusted free operating cash flow, and recent FDA approval of Ziihera, alongside strategic acquisitions.
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale
Jazz Pharmaceuticals plc (JAZZ) officer Renee D. Gala plans to sell up to 2,000 shares of the company’s common stock under Rule 144. The shares, acquired on June 30, 2026, are restricted stock with an aggregate market value of $486,060 as of September 8, 2026, and will be sold through Morgan Stanley Smith Barney LLC. This filing provides details on the planned sale and key financial metrics.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals plc announced its participation in four upcoming investor conferences in September 2026. Company management will engage in fireside chats at the Wells Fargo 21st Annual Healthcare Conference, Citi 2026 Biopharma Back to School Summit, Morgan Stanley 24th Annual Global Healthcare Conference, and Deutsche Bank Healthcare Summit. Audio webcasts of these sessions will be available on the company's investor relations website, with replays archived for 30 days.
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz Pharmaceuticals (JAZZ) saw its shares drop 6.9% since its last earnings report, underperforming the S&P 500 despite a revenue beat in Q2 2026. The company missed EPS estimates due to IPR&D expenses but saw strong sales growth in its oncology and neuroscience products, leading to raised revenue guidance for 2026. Investors are now watching whether this negative trend will persist or if the stock is due for a rebound.
Cancer drug decision could swing Jazz Pharmaceuticals' beat - Bizwomen
Jazz Pharmaceuticals is awaiting an FDA decision on a new use for its cancer drug Ziihera, which could mark the ninth Bay Area drug to receive FDA approval this year. This decision comes as CEO Renee Gala, who took over in August 2025, works to transition Jazz from a specialty pharma company to an innovator developing its own drugs. Gala recently orchestrated the acquisition of Actio Biosciences for up to $1.32 billion, further expanding Jazz's portfolio beyond its historical single-product reliance.
Jazz stock gains on FDA nod for cancer therapy (JAZZ:NASDAQ)
Jazz Pharmaceuticals (JAZZ) stock gained after the company announced FDA approval for two regimens containing its cancer therapy, Ziihera. The therapy was developed in collaboration with BeOne Medicines (ONC) and under licensing deals from Zymeworks (ZYME). This approval marks a significant development for the Irish biopharma company and its partners.
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD By Investing.com
Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $265.54, marking a 109.94% increase over the past year. The company, valued at $17.09 billion, has a P/E ratio of 17.68 and is considered undervalued by InvestingPro. Analysts have revised earnings upwards, and the company reported strong Q2 revenue, although EPS fell short due to dilution and R&D expenses.
Jazz Pharmaceuticals stock hits all-time high at 265.54 USD
Jazz Pharmaceuticals PLC's stock reached an all-time high of $265.54, marking a 109.94% increase over the past year. The company, valued at $17.09 billion, is considered undervalued by InvestingPro analysis despite beating revenue expectations in the second quarter. Analyst firms have raised their price targets for JAZZ, citing strong performance in its diversified portfolio and key products.
Jazz Pharma's fresh tune: New CEO wants to make longtime Bay Area drugmaker 'a true innovator'
Renee Gala is set to become the new CEO of Jazz Pharmaceuticals on August 11. Her goal is to transform the longtime Bay Area drugmaker into a true innovator. A year into her tenure, the company anticipates a potential new drug approval for a product licensed under the previous leadership.
Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ
Advisors Preferred LLC recently acquired a new stake of 20,861 shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), valued at approximately $5.079 million. Other institutional investors have also adjusted their positions in the company, which saw its stock open at $248.70 with a market cap of $16.15 billion. The pharmaceutical company recently missed analysts' consensus earnings estimates but reported a 15.5% increase in revenue year-over-year.
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor attention due to its HER2 pipeline progress, particularly for gastroesophageal adenocarcinoma, and is currently deemed 11.6% undervalued with a fair value of $281.35. Despite a recent share price pullback, the company shows strong year-to-date and one-year returns, driven by R&D, commercialization efforts, and international expansion, although potential risks like generic pressure and trial underperformance exist.
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative
Jazz Pharmaceuticals (JAZZ) is gaining investor interest due to its progress in HER2 pipeline development for cancers, leading to a 106.3% one-year total shareholder return. Despite a recent slight share price pullback, the company is considered 11.6% undervalued with a fair value of $281.35, driven by rare-disease pricing, a maturing neuroscience franchise, and international oncology scaling. Investors should also consider risks like generic drug pressure and trial underperformance.
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ
Great Lakes Advisors LLC has acquired a new stake of $8.15 million in Jazz Pharmaceuticals PLC, purchasing 33,804 shares in the second quarter. This move makes Great Lakes Advisors LLC own approximately 0.05% of the company's stock. The article also details recent insider stock sales, other hedge fund activities, analyst ratings, and the company's financial performance.
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks
This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (J7Z). It provides detailed information for each ETF, including market value, weight of J7Z stock, issuer, management style, focus, expense ratio, assets under management (AUM), current price, percentage change, relative volume, and 3-year NAV total return. The ETFs cover different market segments such as mid-cap, total market, small-cap, extended market, large-cap, and healthcare, offering diverse investment opportunities with varying risk profiles.
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion
Irish biopharmaceutical company Jazz Pharmaceuticals plc has announced its acquisition of American Actio Biosciences, Inc. for $1.32 billion. The deal involves an upfront payment of $820 million and an additional $500 million contingent on drug approval and sales milestones. Jazz will gain control of ABS-1230, a drug for a rare form of childhood epilepsy, while Actio Biosciences will form a new independent company focusing on rare genetic neurological diseases.
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 96.7% in the second quarter, selling 309,427 shares and retaining 10,573 shares valued at $2.55 million. Despite this, institutional investors and hedge funds collectively own 89.14% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $272.89. The company reported quarterly revenue of $1.21 billion, exceeding estimates, though adjusted EPS missed consensus.
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Jazz Pharmaceuticals (JAZZ) stock has shown a significant return of 112.6% over the past year. Despite this performance and recent deal activity, the stock appears undervalued based on its P/E ratio of 17.2x, which is on par with the industry average but significantly lower than a peer group average of 28.8x and its estimated fair P/E of 24.7x. The market's current valuation of JAZZ suggests a mixed picture, not a clear bargain, with the company's ability to execute on its pipeline and manage risks being key to future performance.
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ
Wedge Capital Management L L P NC reduced its stake in Jazz Pharmaceuticals PLC by 20.9% in the second quarter, selling 33,467 shares and retaining 126,539 shares valued at approximately $30.5 million. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, and analysts generally maintain a "Moderate Buy" rating with an average target price of $272.89. The article also highlights recent insider selling activity and the company's strategic acquisition of Actio Biosciences to expand its rare epilepsy portfolio, a move seen as strategically sensible but with inherent clinical development and commercialization risks.
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional contingent payments of up to $500 million. This deal includes Actio Biosciences spinning out a new company focused on genetic rare neurological diseases, in which Jazz will hold a minority equity interest. The acquisition significantly expands Jazz's rare epilepsy portfolio with Actio's main clinical asset, ABS-1230, a small molecule inhibitor for KCNT1+ epilepsy, which has secured FDA fast track, rare pediatric disease, and orphan drug product designations.
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ
Royal Bank of Canada increased its stake in Jazz Pharmaceuticals PLC by 17.4% in the first quarter, now holding 45,251 shares valued at $8.56 million. Institutional investors collectively own 89.14% of JAZZ shares, reflecting positive sentiment despite a recent EPS miss. Jazz Pharmaceuticals reported strong revenue growth and raised its 2026 outlook, maintaining a "Moderate Buy" consensus rating among analysts.
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a private biotech specializing in genetic epilepsy treatments, for an upfront payment of $820 million and potential milestone payments of $500 million, totaling $1.3 billion. The acquisition will bolster Jazz's neuroscience pipeline, particularly with Actio's lead drug candidate, ABS-1230, which targets a rare form of epilepsy caused by KCNT1 gene mutations and is currently in a 55-participant study. This deal reflects a broader trend of increased private biotech buyouts, with Jazz leveraging its cash reserves and existing financing to fund the transaction.
Jazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion
Jazz Pharmaceuticals is set to acquire Actio Biosciences in a deal valued at up to $1.32 billion, significantly expanding its rare epilepsy portfolio. The acquisition centers on ABS-1230, Actio's clinical-stage precision medicine for KCNT1-related epilepsy, a rare genetic disorder. The deal includes an $820 million upfront payment and up to $500 million in milestone payments, with Actio spinning out its other pipeline assets into a new independent company.
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M
Jazz Pharmaceuticals announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional payments of up to $500 million tied to milestones. The acquisition is primarily focused on ABS-1230, a clinical-stage drug for KCNT1+ epilepsy, a rare genetic disorder with no currently approved therapies. Actio Biosciences will spin off a new entity for other neurological diseases, in which Jazz will hold a minority stake.
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio
Jazz Pharmaceuticals (JAZZ) announced its acquisition of Actio Biosciences for $820 million upfront and up to $500 million in milestone payments, expected to close by late 2026. This strategic move strengthens Jazz's rare epilepsy portfolio with the addition of ABS-1230, a promising therapy for ultra-rare KCNT1+ epilepsy. Actio's other genetic neurology assets will be spun out into a new private company where Jazz will hold a minority stake.
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history
This article provides a detailed overview of Jazz Pharmaceuticals plc (JAZZ), including its stock price, news, and historical data. It covers the company's financial performance, product pipeline, analyst ratings, and compares it with similar biotechnology companies. The information presented aims to give investors a comprehensive look at JAZZ's market position and prospects.
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Jazz Pharmaceuticals PLC (JAZZ), highlighting its current earnings forecast score, average price target, and analyst ratings. It details expected future EPS and revenue growth, along with recent performance and a peer comparison. The forecast indicates a "Buy" trend based on analyst consensus, with an expected revenue of $1.21 billion for the next quarter.
Jazz Pharmaceuticals plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:JAZZ) 2026-08-07
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $5.71, missing estimates by $0.47, but revenue reached $1.21 billion, surpassing expectations by $93.90 million with a 15.55% year-over-year increase. This presentation provides stakeholders with key financial insights from the recent quarter.
